$17.36-0.48 (-2.69%)
Stevanato Group S.p.A.
Stevanato Group S.p.A. in the Healthcare sector is trading at $17.36 with a market capitalization of $4.5B. Wall Street consensus targets $24.45 (10 analysts), implying a +40.8% move over the next 12 months. The stock is currently 38% below its 52-week high of $28.00, remaining 10.6% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $273.57M↓ | $346.48M↑ | $303.17M↑ | $280.00M↑ | $256.60M |
| Gross Profit | $75.18M↓ | $106.90M↑ | $88.50M↑ | $78.60M↑ | $69.89M |
| Operating Income | $38.74M↓ | $70.08M↑ | $52.72M↑ | $41.40M↑ | $34.63M |
| Net Income | $28.03M↓ | $47.55M↑ | $36.06M↑ | $29.70M↑ | $26.52M |
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. ...
Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Stevanato Group stock overview after recent performance moves Stevanato Group (STVN) stock has been under pressure recently, with the price down 1.2% over the past day, 7.5% over the past week, and about 5% over the past month. That shorter term weakness sits alongside a gain of roughly 11% over the past 3 months, set against a decline of about 17% year to date and around 27% over the past year for long term holders. See our latest analysis for Stevanato Group. With the share price at $17.08,...
Is STVN a good stock to buy? We came across a bullish thesis on Stevanato Group S.p.A. on Best Anchor Stocks’s Substack. In this article, we will summarize the bulls’ thesis on STVN. Stevanato Group S.p.A.’s share was trading at $18.10 as of June 9th. STVN’s trailing and forward P/E were 30.80 and 19.46 respectively according to […]
Italian healthcare vials and cartridges maker Stevanato Group and U.S. generic and wholesale pharmaceutical company Cencora are two of the best healthcare buys right now.
Investors need to pay close attention to STVN stock based on the movements in the options market lately.